185 материалов по теме, собраны автоматически из проверенных источников
Scientists at UC San Francisco have developed a way to create cancer-fighting CAR-T cells directly inside the body, potentially avoiding the slow and extremely expensive process of removing, engineering, and reinfusing a patient’s immune cells. Using a two-particle delivery system, the researchers sent CRISPR…
Учёные нашли возможную мишень для CAR-T-терапии в солидных опухолях Life4me+
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial PR Newswire
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial Morningstar
Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK that can push T cells to burn through their energy while producing…
Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting BioSpace
Christopher Steer: Australia Advances Tumor-Agnostic Immunotherapy Access Oncodaily
Immunotherapy Breakthroughs and Single-Cell Atlas Studies Reshape Liver Cancer Care in China Bioengineer.org
George L. Kumar: How a Virus Hunt Led to Cancer Immunotherapy Oncodaily
Jonathan Lim: Rethinking Immunotherapy for Brain Tumours at MION Oncodaily
Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting Business Wire
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods. The test also allows physicians not only to assess the cancer's response to treatment but also to predict whether immunotherapy or…
Michail Ignatiadis Explores Whether PD-(L)1×VEGF Could Become the Next Immunotherapy Backbone Oncodaily
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial PR Newswire
Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefits only 17%–23% of patients with head and neck squamous cell carcinoma. These are cancers that arise from…